Meanwhile, after the UK variant made inroads into various cities of the country, Pakistan has reported its first confirmed patient carrying the Indian strain.
The jab, produced by Serum Institute of India under licence from the US-based Novavax, will now be distributed as part of global vaccine-sharing system Covax, "giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries", WHO said in a statement.
The health authorities said the body's immune system recognises the foreign organism and produces antibodies to fight it.
Senior health official Vinod Kumar Paul told a news briefing that government experts were studying data on boosters but "our emphatic view...is to (first) cover every adult with (just) the primary two doses." The government has said this target can be achieved by January.
"At a time where the Omicron variant is rapidly spreading, and where we need to step up vaccination and the administration of boosters, I am particularly pleased with today's authorisation of the Novavax vaccine," said EU chief Ursula von der Leyen.
The new vaccine will be produced and distributed by Hayat Biotech, a JV between G42 and Sinopharm CNBG, while the vaccine will be available to the public as a booster dose starting January 2022 as part of the measures taken to contain the virus spread.
The new “Sinopharma Recombinant Protein Vaccine” and “Sinopharma Vaccine” are both effective for producing antibodies, but the “New Sinopharm Recombinant Protein Based Vaccine” can achieve larger production to ensure more efficacy to prevent mutant.
Omicron infections have so far caused "mild" illness or asymptomatic cases, but the WHO said the data was insufficient to establish the variant's clinical severity.
"The Kingdom of Saudi Arabia has granted approval for entry of individuals vaccinated with the Russian Sputnik V vaccine starting from Jan.1, 2022," the Russian Direct Investment Fund (RDIF), which financed the development of Sputnik V, said in a statement.